Amphastar Reports Financial Results For The Three Months And Fiscal Year Ended December 31, 2016 Post author:Sam Post published:March 13, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Clarus Ventures Wants To Pick Up The Tab For Big Pharma's R&D With New $910 Million Fund July 17, 2017 Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017 San Diego's Mirati Therapeutics Abandons Lead Drug, Shifts Focus November 14, 2017
Clarus Ventures Wants To Pick Up The Tab For Big Pharma's R&D With New $910 Million Fund July 17, 2017
Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma February 2, 2017